GSK and Vir Biotechnology COVID-19 drug found to reduce deaths and hospitalisation by 85%
March 11, 2021GSK, GlaxoSmithKline, Vir Biotechnology
Vir Biotechnology and GSK have announced that their monoclonal-antibody drug has been found to reduce hospitalisations or deaths from COVID-19 …
FDA approves AVEO’s kidney cancer treatment
March 11, 2021Aveo, FDA, Kidney cancer, fotivda, rcc
The FDA has approved AVEO Oncology’s FOTIVDA drug for the treatment of adults with relapsed or refractory advanced renal cell …
Complix and I-Mab sign deal to develop alphabody cancer therapies
March 11, 2021Cancer, Complix, oncology
Biopharmaceutical company Complix has signed a drug discovery deal with I-Mab Biopharma, a clinical-stage company focused on the discovery, development, …
GSK to expand cell and gene therapy manufacturing capacity at CGT Catapult’s Stevenage site
March 11, 2021GlaxoSmithKline (GSK) will expand its clinical trial manufacturing capacity for advanced therapy medicinal products (ATMP) at Cell and Gene Therapy …
Pharmafile.com’s weekly COVID-19 news round-up
March 10, 2021Research and Development COVID, COVID Vaccine, COVID-19, coronavirus, covid round-up
The past week has continued to see positive COVID-19 news; CytoDyn’s treatment for patients with severe symptoms of the virus …
Lilly’s cancer drug Retsevmo gets UK approval for multiple indications
March 10, 2021Research and Development Cancer, Eli Lilly, MHRA
The MHRA has granted conditional marketing authorisation for Eli Lilly’s Retsevmo (selpercatinib) as monotherapy for a number of cancer indications.
Takeda acquire Maverick in $525m deal to expand cancer therapy portfolio
March 10, 2021Research and Development Maverick, Takeda, cancer treatment
Takeda has acquired Maverick Therapeutics in a deal worth up to $525 million, in order to expand its portfolio of …
Evonik and Cassava Sciences enter supply agreement for Alzheimer’s drug candidate
March 10, 2021Research and Development Alzheimer's, Cassava Sciences, Evonik
Evonik has entered into an agreement to supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for …
Affinivax receives $22m funding for development of Staphylococcus aureus vaccine
March 10, 2021Research and Development Affinivax, bacteria, vaccines
Affinivax has received an award of $22 million funding from CARB-X, a global non-profit organisation, to develop a vaccine targeting Staphylococcus …
CytoDyn’s COVID-19 treatment shows positive results in Phase III trial
March 9, 2021Manufacturing and Production cytodyn, phase 3 trial, vyrologix
Biotechnology company CytoDyn has shown positive results in its Phase III CD12 trial of Vyrologix, its treatment for COVID-19 patients …
FDA approves Kite’s Yescarta therapy for follicular lymphoma
March 9, 2021Manufacturing and Production FDA, Kite, Yescarta
The FDA has granted accelerated approval to Kite’s Yescarta treatment, a medicine for adult patients with relapsed or refractory follicular …
Camallergy awarded £1.1m government funding for peanut allergy immunotherapy
March 9, 2021Manufacturing and Production Camallergy, UK, allergy
Camallergy, a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded …
Valo and ImmunoScape collaboration identifies immunogenic peptides for pan-coronavirus vaccine
March 9, 2021Manufacturing and Production COVID-19, Valo Therapeutics, immunoscape, vaccines
Immunotherapy platform developer Valo Therapeutics has successfully completed a collaboration with the biotechnology company ImmunoScape to identify immunogenic peptides for …
Novartis’ canakinumab fails to improve lung cancer survival in Phase III study
March 9, 2021Manufacturing and Production Cancer, Novartis, lung cancer
Novartis has announced that the Phase III CANOPY-2 study evaluating canakinumab, an inhibitor of interleukin-1beta (IL-1β), in combination with the chemotherapy agent …
CHMP recommends Lilly’s bamlanivimab for COVID-19 patients
March 8, 2021Sales and Marketing COVID-19, EMA, Eli Lilly
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for Eli Lilly’s bamlanivimab …
FDA grants Priority Review to Korsuva for CKD-associated pruritis
March 8, 2021Sales and Marketing Cara Therapeutics, FDA, Korsuva
The FDA has accepted and granted Priority Review for the new drug application (NDA) for Cara Therapeutics’ Korsuva (difelikefalin) solution …
NICE recommends £1.79m gene therapy for spinal muscular atrophy in babies
March 8, 2021Sales and Marketing NICE, spinal muscular atrophy
NICE is set to approve a new and potentially curative one-off gene therapy for babies with the rare genetic disorder …
ViiV presents positive long-term data for combined HIV treatment
March 8, 2021Sales and Marketing HIV, ViiV Healthcare
ViiV Healthcare has presented positive long-term data from its global Phase IIIb ATLAS-2M study of the first complete, long-acting regimen …
Roche voluntarily withdraws Tecentriq’s US bladder cancer indication
March 8, 2021Sales and Marketing Cancer, Roche, bladder cancer, tecentriq
Roche has announced that the company is voluntarily withdrawing the US indication for Tecentriq (atezolizumab) in prior-platinum treated metastatic urothelial …
Pharmafile.com’s top 10 news stories of the week
March 5, 2021Medical Communications COVID, COVID-19, COVID-19 vaccine, news roundup, pharma news, roundup
The last week has seen its fair share of COVID-19 vaccine developments; Bharat Biotech’s candidate was found to be 81% …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
